Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non-Carfilzomib-Based Regimens in the United States by Race

CONCLUSION: Although the IR of heart failure among patients with MM treated with a carfilzomib-based regimen was slightly higher, no evidence suggested the relative risk was different between White and Black patients with MM.PMID:37258396 | DOI:10.1016/j.clml.2023.04.009

Source: Clinical Lymphoma and Myeloma - May 31, 2023 Category: Cancer & Oncology Authors: Shuling Li Brandon T Suehs Alan Fu Laura Sangar é Chris Kim Victor M Gastanaga Jiannong Liu Heng Yan Yihua Xu Joseph Mikhael Source Type: research